Home › Research › Treatments
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials
Raschetti R, Albanese E, Vanacore N, Maggini M.. PLoS medicine, 2007-11-01
Topic: Risk, prevention and care in population studies
No significant differences emerged in the probability of conversion from MCI to AD or dementia between the treated groups and the placebo groups. Statistically significant differences emerged for three secondary end points. However, when adjusting for multiple comparisons, only one difference remained significant (i.e., the rate of atrophy in the whole brain). Conclusions The use of ChEIs in MCI was not associated with any delay in the onset of AD or dementia. Moreover, the safety profile showed that the risks associated with ChEIs are not negligible.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M. (2007). Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS medicine. https://doi.org/10.1371/journal.pmed.0040338
Vancouver
Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS medicine. 2007. doi:10.1371/journal.pmed.0040338. PMID: 18044984.
BibTeX
@article{raschetti2007-18044984,
author = {Raschetti, R. and Albanese, E. and Vanacore, N. and Maggini, M.},
title = {{Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials}},
journal = {PLoS medicine},
year = {2007},
doi = {10.1371/journal.pmed.0040338},
pmid = {18044984},
url = {https://doi.org/10.1371/journal.pmed.0040338}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- No significant differences emerged in the probability of conversion from MCI to AD or dementia between the treated groups and the placebo groups.
- Statistically significant differences emerged for three secondary end points.
- However, when adjusting for multiple comparisons, only one difference remained significant (i.e., the rate of atrophy in the whole brain).
- Conclusions The use of ChEIs in MCI was not associated with any delay in the onset of AD or dementia.
- Moreover, the safety profile showed that the risks associated with ChEIs are not negligible.
Why it matters
This review found that cholinesterase inhibitors did not delay the onset of Alzheimer's disease or dementia in people with mild cognitive impairment. It also reported that the risks associated with these drugs are not negligible.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 62/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PLoS medicine) |
| Journal's citation record | 3 / 4 | PLoS Medicine: journal h-index 350 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question (from PubMed type “Systematic Review”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | 6 / 7 | Cited 322 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.3 citations a year over 21 year(s) since 2007 |
| Impact for its field and year | 3 / 6 | Cited 3.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 21 other studies in this library |
| Still being cited | 2 / 4 | Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Marina Maggini: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | King's College London: institution h-index 1,348 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18044984) |
| Free to read | 2 / 2 | Free to read |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1371/journal.pmed.0040338
- PubMed: 18044984
- Original source →
- Free full text: PLoS Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
21 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “examination”
840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.